Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Marriott Wardman Park Hotel

27 ene 2020 7:00 a.m. - 29 ene 2020 4:15 p.m.

2660 Woodley Road, NW, , Washington, DC 20008 , USA

Pharmacovigilance and Risk Management Strategies Conference

Session 12: The Lifecycle of a REMS

Session Chair(s)

Jill K. Logan, PharmD

Jill K. Logan, PharmD

Safety Evaluator, DPV I, OSE, CDER

FDA, United States

Ingrid N. Chapman, PharmD

Ingrid N. Chapman, PharmD

Senior Risk Management Analyst, DRM, OMEPRM, OSE, CDER

FDA, United States

Risk evaluation and mitigation strategies (REMS) are drug safety programs required by FDA and developed by manufacturers to ensure the benefit of a drug or biologic product outweighs its risk. Risk management is an iterative process that includes assessing the drug’s benefit-risk balance, developing and implementing tools to minimize risks while preserving benefits, evaluating the effectiveness of the intervention(s) and adjusting, as appropriate. REMS are designed to mitigate a specific risk by reinforcing medication use behaviors and actions that support the safe use of the drug product. Following approval of a REMS, it is important to assess the effectiveness of the REMS and to consider if there are opportunities to improve the implementation of the REMS to reduce the burden to stakeholders. This session examines REMS development, implementation, assessments, and modifications which will be discussed and illustrated with examples.

Learning Objective :

At the conclusion of this session, participants should be able to:

  • Link interventions to measurable outcomes
  • Identify pathways to REMS modifications
  • Discuss how post-marketing data or assessments may impact the REMS and lead to modification

Speaker(s)

Shelly  Harris, DrSc, MPH

Speaker

Shelly Harris, DrSc, MPH

FDA, United States

REMS Assessment Team Leader, OSE, CDER

Catherine  Baldridge, MSc

Speaker

Catherine Baldridge, MSc

Fusion Pharmaceuticals, United States

Head of Safety

Elisa  Gomez-Reino, MPH

REMS Changes Over Time

Elisa Gomez-Reino, MPH

Alexion Pharmaceuticals, Inc., United States

Senior Director, Regional Safety Excellence US and Canada

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.